Original Research

Effect of Dapagliflozin on HbA1c in Type 2 Diabetics: A Descriptive Prospective Uncontrolled Before and After Study

Nida Anjum1
Rawalpindi Medical University
Madeeha Nazar1
Rawalpindi Medical University
Saba Arshad1
Rawalpindi Medical University
Fasih Hashmi1
Rawalpindi Medical University
Sadia Azam Khan2
Allama Iqbal Open University
Iram Shad1
Rawalpindi Medical University

✉ Correspondence: Madeeha Nazar Email: madeehanazar@gmail.com

DOI https://doi.org/10.70302/jpsim.v6i2.2532
Volume: 6, Issue 2 Pages: 170–174 Published: 05 Jun 2025
Received: 09 Dec 2024 Revised: 18 Jan 2025 Accepted: 02 May 2025 Published Online: 05 Jun 2025

Abstract

Objective

To determine the efficacy of Dapagliflozin and its effect on HbA1c in Type 2 Diabetic patients.

Methods

We had conducted our descriptive study in the outdoor patient department of Holy Family Hospital, Rawalpindi. Hundred, Type 2 diabetic patients of both genders were enrolled through consecutive sampling to assess the efficacy of Dapagliflozin, an SGLT2 inhibitor in a Pakistani population. Those patients with HbA1c of ≥ 7% who had fulfilled our inclusion criteria were given Dapagliflozin 10mg as either monotherapy or add-on therapy. HbA1c, BP, and body weight were noted at the start of drug therapy and after 12 weeks of drug use. The primary endpoint was ≥ a 10% relative percentage reduction of HbA1c after 12 weeks.

Results

Out of 100 subjects there were 40 males and 60 females in our sample. The average age of the patients was 49.37±11.38 years. Dapagliflozin was given as a monotherapy to only two patients and others as an add on the drug. The average relative percent reduction after 12 weeks of treatment in HbA1c was 11.68±6.20. The sample results showed that the drug Dapagliflozin is effective for 62% of patients hence based on the sample results we conclude that the Dapagliflozin is effective against type 2 diabetics in our population for at least 53% of patients with a p-value of 0.034.

Conclusion

Over the period of 12 weeks, Dapagliflozin has shown a significant reduction in HbA1c and body weight of Type 2 diabetics in the Pakistani population. Once-daily dosing and a low rate of hypoglycemia make it a cost-effective and safe drug as well.

Keywords
Hb A1c SGLT-2 inhibitors Dapagliflozin.

How to Cite This Article

Anjum N, Nazar M, Arshad S, Hashmi F, Khan SA, Shad I. Effect of Dapagliflozin on HbA1c in Type 2 Diabetics: A Descriptive Prospective Uncontrolled Before and After Study. J Pak Soc Intern Med. 2025;6(2):170–174. doi:10.70302/jpsim.v6i2.2532

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. Soren Brandt Poulsen, Robert A. Fenton, Timo Rieg. Sodium-glucose cotransporter. Curr Opin Nephrol Hypertens. 2015; 24(5):436-439.
  2. Beatrice C. Lupsa, Silivio E. Inzucchi. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018; 61:2118-25.
  3. Han E, Kim A, Lee SJ, Kim JY, Kim JH, Lee WJ, et al. Characteristics of Dapagliflozin Responder: A longitudinal 3, prospective, nationwide Dapagliflozin Surveillance study in Korea. Diabetes Ther. 2018; 9(8):1681- 1701.
  4. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetics with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetic Care. 2010; 33(10):2217-24.
  5. Van Baar MJ, Van Ruiten CC, Muskiet MH, Van Bloemendaal L, IJzerman RG, Van Raalte DH. SGLT2 inhibitors in combination therapy: From Mechanisms to clinical considerations in Type 2 Diabetes Management. Diabetes Care. 2018; 41(8):1543-56.
  6. Brown RE, Gupta N, Aronson R. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Diab Technol Therapeut. 2017;19(11):685-91.
  7. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, et al. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes. J Atheroscler Thromb. 2018;25(6):467-76.
  8. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diab Obes Metabol. 2010;12(6):510-6.
  9. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde A, Sjöström C, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diab Obes Metabol. 2014;16(2):159-69.
  10. Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Therap Adv Drug Safety. 2014;5(6):242-54.
  11. Henry R, Murray A, Marmolejo M, Hennicken D, Ptaszynska A, List J. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial. Int J Clin Pract. 2012;66(5):446-56.
  12. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473-8.
  13. Strojek K, Yoon K, Hruba V, Elze M, Langkilde A, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial. Diab Obes Metabol. 2011;13(10):928-38.
  14. Wilding J, Woo V, Rohwedder K, Sugg J, Parikh S, Group DS. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diab Obes Metabol. 2014;16(2):124-36.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2025 Journal of Pakistan Society of Internal Medicine.
📃 In This Issue View All
Review Article Thyroid Disorders in Pregnancy: Clinical Implications and Management Strategies Baig BI, Usman A Original Article Prevalence of Hypertension Among Urban Adults in Pakistan: A Cross-Sectional Study Khan TM, Ahmed S, Malik RA Original Article Comparison of Ultrasound-Guided versus Landmark-Based Central Venous Catheter Insertion Zafar S, Gillani SA Review Article Statin Therapy in Non-Alcoholic Fatty Liver Disease: A Systematic Review Nawaz F, Cheema HA, Mehmood Y Original Article Serum Ferritin as a Prognostic Marker in COVID-19 Severity: A Hospital-Based Study Rehman N, Sheikh I, Javed K
👥 More by These Authors
Original Article Neonatal Sepsis: Bacteriological Profile and Antibiogram in a Tertiary Care Hospital Iqbal M, Rashid T Original Article Outcomes of Laparoscopic Cholecystectomy in Acute Cholecystitis: A Retrospective Analysis Raza SH, Butt N, Qureshi AM Review Article Antibiotic Resistance Patterns in Community-Acquired Pneumonia: Emerging Trends Hussain I, Farooq Z Original Article Impact of Diabetes Mellitus on Post-Operative Wound Healing in General Surgery Siddiqui FA, Noor M, Akhtar W
🔗 Related Articles By Keywords
Original Article Comparison of Ultrasound-Guided versus Landmark-Based Central Venous Catheter Insertion Zafar S, Gillani SA Review Article Statin Therapy in Non-Alcoholic Fatty Liver Disease: A Systematic Review Nawaz F, Cheema HA, Mehmood Y Original Article Serum Ferritin as a Prognostic Marker in COVID-19 Severity: A Hospital-Based Study Rehman N, Sheikh I, Javed K Original Article Cervical Cancer Screening Awareness Among Rural Women in Punjab Bibi S, Anjum R, Hassan F